<DOC>
	<DOCNO>NCT01676779</DOCNO>
	<brief_summary>This open label , 2-arm , 1-stage , randomize control phase II study patient AJCC stage IIIB/C &amp; -IV melanoma . At baseline tumor assessment ( use total body FDG-PET/CT ) , patient free measurable tumor lesion ( accord RECISTv1.1 definition ) follow prior local therapy ( e.g . follow surgical resection , isolated limb perfusion , radiofrequency ablation , cryotherapy , radiotherapy , electrochemotherapy , … ) . Patients symptomatic non-measurable tumor lesion ( e.g . bone metastasis , pleural effusion ) , lesion treat prior local therapy free progression . Patients receive prior systemic therapy ( non-experimental experimental ) .</brief_summary>
	<brief_title>mRNA Electroporated Autologous Dendritic Cells Stage III/IV Melanoma</brief_title>
	<detailed_description>This open label , 2-arm , 1-stage , randomize control phase II study patient AJCC stage IIIB/C &amp; -IV melanoma . At baseline tumor assessment ( use total body FDG-PET/CT ) , patient free measurable tumor lesion ( accord RECISTv1.1 definition ) follow prior local therapy ( e.g . follow surgical resection , isolated limb perfusion , radiofrequency ablation , cryotherapy , radiotherapy , electrochemotherapy , … ) . Patients symptomatic non-measurable tumor lesion ( e.g . bone metastasis , pleural effusion ) , lesion treat prior local therapy free progression . Patients receive prior systemic therapy ( non-experimental experimental ) . - Patients randomize two treatment arm ( Arm-A -B ) . In study Arm-A , patient receive DC-administrations one year follow randomization . Salvage treatment local therapy allow study treatment Arm-A . In study Arm-B , patient initiate DC-administrations document recurrence melanoma salvage local therapy . - The primary endpoint clinical trial determine rate ( % ) patient free macrometastases ( : measurable tumor lesion symptomatic non-measurable tumor lesion ) 1-year ( = 52 week ) randomization . Patients treat Arm-B serve contemporary control-arm help interpret outcome patient treat Arm-A . By design ( phase II ) trial power statistically prove predefined difference two study arm ( would require phase III design ) . Patients treat Arm-B able initiate immunotherapy autologous DC time recurrence salvage local therapy . Documentation anti-tumor activity survival follow DC-treatment recurrence Arm-B patient secondary objective clinical trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Able willing give write informed consent 2 . Histological documentation AJCC stage III stage IV melanoma 3. melanoma ( melanoma originate choroid , iris ciliar body eligible ) 4. baseline tumor assessment wholebody FDGPET/CT , patient free measurable tumor lesion ( RECIST ( v1.1 ) ) , free symptomatic nonmeasurable tumor lesion 5 . Prior local treatment primary metastatic tumor lesion allow . Treated tumor lesion free progression baseline assessment 6 . Normal organ function normal hematological parameter ; laboratory parameter within normal range , except follow laboratory parameter : HEMOGLOBIN ≥ 10 G/DL ; GRANULOCYTES ≥ 1,500/µL ; LYMPHOCYTES ≥ 1000/µL ; PLATELETS ≥ 100,000/µL ; SERUM CREATININ ≤ 2.0 MG/DL ; SERUM BILIRUBIN ≤ 2.0 MG/DL ; AST AND ALT ≤ 2 X THE NORMAL UPPER LIMITS ; LDH ≤ 1,5X NORMAL UPPER LIMIT ; CRP ≤ 1,5X NORMAL UPPER LIMIT ; PROTHROMBIN TIME ( PT ) INTERNATIONAL NORMALIZED RATIO ( INR ) AND PARTIAL THROMBOPLASTIN TIME ( PTT ) WITHIN NORMAL LIMITS 7 . Negative serology HCV , HIV ; absence active infection HBV , Syphilis ; If positive result HepB Syphilis indicate immunity indicative active infection , patient enter study . 8 . Adequate venous access ( undergo leukapheresis ) 9 . No prior systemic therapy melanoma 10 . Full recovery prior therapy . A period 4 week follow major surgery , radiation therapy , ILP , major invasive procedure require 11 . Baseline WHO performance status 0 1 12 . Male female patient ≥ 18 year 13 . No need uninterrupted therapeutic anticoagulation 14 . No prior history serious autoimmune disorder 15 . No concomitant medication immune suppressive drug 16 . Women childbearing potential must use adequate method contraception avoid pregnancy throughout study 8 week study manner risk pregnancy minimize . 1 . Evidence immunodeficiency autoimmune disease require medical treatment ( e.g . corticosteroid immunosuppressive drug ) .Vitiligo exclusion criterion 2 . Any serious acute chronic illness ( e.g . heart disease NYHA Class III IV , renal , liver pulmonary insufficiency ) condition require concurrent medication allow study ( e.g . active chronic infection require antibiotic ) 3 . History malignancy . Curatively treated cervical carcinoma situ , squamous , basal cell carcinoma skin , subject treat recurrencefree malignancy 5 year follow diagnosis eligible 4 . Inability undergo FDGPET/CT , MRI examination 5 . Mental impairment may compromise ability give informed consent comply requirement study 6 . Participation clinical trial involve another investigational agent within 4 week prior enrollment 7 . Subject pregnant ( positive serum betaHCG test screening ) currently breastfeed , anticipate become pregnant/impregnating partner study within 6 month study participation , subject agree follow acceptable method birth control , avoid conception study least 6 month receive last dose study treatment 8 . Current alcohol dependence drug abuse 9 . Known hypersensitivity study treatment 10 . Legal incapacity limit legal capacity 11 . Presence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule . 12 . Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>evidence disease</keyword>
	<keyword>resection</keyword>
	<keyword>macro-metastases</keyword>
</DOC>